ClinicalTrials.gg
TerminatedNCT03736967Updated Nov 1, 2021Results posted

Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis

A Phase 2 interventional study of REGN3500 and Dupilumab in Atopic Dermatitis, sponsored by Regeneron Pharmaceuticals. Terminated at 66 sites in 7 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-11-01.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

Why this study was terminated
Lack of efficacy

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
206
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing dupilumab in Dermatitis, Atopic — 4 open to participants now, 6 under way, none of them phase 3. dupilumab · Dermatitis, Atopic.

Enrollment
15th of 50
206 · median 75
Started
2018
with 4 others
Phase 2
7 of 50
none open now
Registered
23rd of 50
by date
Lead sponsor
22 of 50
Regeneron Pharmaceuticals

Among the 50 studies testing dupilumab in Dermatitis, Atopic, this one is the 15th largest by enrollment, is one of 5 that started in 2018, is one of 7 in phase 2, and was the 23rd registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

4 of the 50 studies testing dupilumab in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About dupilumab

dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing dupilumab in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The primary objective of the study is to evaluate the efficacy of REGN3500 monotherapy compared with placebo treatment in adult patients with moderate-to-severe Atopic dermatitis (AD).

Secondary Objectives are to:

  • Evaluate the efficacy of REGN3500 in combination with dupilumab compared with placebo treatment in adult patients with moderate-to-severe AD
  • Assess the safety, tolerability, and immunogenicity of subcutaneous (SC) doses of REGN3500 monotherapy and REGN3500 in combination with dupilumab in adult patients with moderate-to-severe AD
  • Evaluate the Pharmacokinetic (PK) of REGN3500 monotherapy and REGN3500 in combination with dupilumab in adult patients with moderate-to-severe AD
03

Conditions studied

  • Atopic Dermatitis

Keywords

  • Moderate
  • Severe
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Chronic AD, according to American Academy of Dermatology Consensus Criteria (Eichenfield, 2014), that has been present for at least 3 years before the screening visit
  2. Eczema Area and Severity Index (EASI) score ≥16 at the screening and baseline visits
  3. ≥10% Body surface area (BSA) of AD involvement at the screening and baseline visits
  4. Documented recent history (within 6 months before the screening visit) of inadequate response to topical AD medication(s) or for whom topical treatments are medically inadvisable

Key Exclusion Criteria:

  1. Prior participation in an anti-Interleukin (IL)-33 class antibody (including but not limited to REGN3500) or anti-IL-4Rα class antibody (including but not limited to dupilumab) clinical study; past treatment with or current treatment with dupilumab or another anti-IL-4Rα treatment
  2. Active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals 2 weeks before the baseline visit, or superficial skin infections within 1 week before the baseline visit
  3. Known or suspected history of , including history of invasive opportunistic infections (eg, tuberculosis (TB), histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis) despite infection resolution: or unusually frequent, recurrent, or prolonged infections, per investigator judgment
  4. History of (HIV) infection or positive HIV serology at screening
  5. Positive with surface antigen (HBsAg), hepatitis B core antibody (HBcAb), or virus antibody (HCV Ab) at the screening visit
  6. Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study

Note: Other protocol defined Inclusion/Exclusion Criteria apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
206 participants (actual)

Study arms

  • Experimental
    REGN3500

    Drug: REGN3500

  • Experimental
    Dupilumab

    Drug: Dupilumab

  • Experimental
    Combo

    Drug: REGN3500 + Dupilumab Combo

  • Experimental
    Placebo

    Drug: REGN3500 · Drug: Dupilumab · Drug: Placebo

Interventions

  • Administered subcutaneous (SC) every 2 weeks (q2w)

  • Administered SC q2w

    Also known as: REGN668, Dupixent

  • DrugREGN3500 + Dupilumab Combo

    Drug page: Dupilumab

    Administered SC q2w

    Also known as: REGN668, Dupixent

  • DrugPlacebo

    Administered SC q2w

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16

    The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, induration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Percent change from baseline in EASI score at Week 16 based on observed values set to missing after rescue treatment was reported. Values after first rescue treatment were set to missing and participants with missing EASI score at Week 16 were counted as non-responders.

    Time frame: Week 16

Secondary outcomes

  1. Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on All Observed Values Regardless of Rescue Treatment at Week 16

    The EASI score was used to measure the severity and extent of AD and measures erythema, induration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Percent change from baseline in EASI score at Week 16 based on all observed values regardless of rescue treatment was reported.

    Time frame: Week 16

  2. Percentage of Participants Who Achieved Eczema Area and Severity Index-50 (EASI-50) (Greater Than or Equal to [≥] 50 Percent [%] Improvement From Baseline) Based on Observed Values Set to Missing After Rescue Treatment at Week 16

    The EASI score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Percentage of participants who achieved EASI-50 (≥50% Improvement from baseline) at Week 16 based on observed values set to missing after rescue treatment were reported. Values after first rescue treatment were set to missing and participants with missing EASI score at Week 16 were counted as non-responders.

    Time frame: Week 16

  3. Percentage of Participants Who Achieved Eczema Area and Severity Index-50 (EASI-50) (≥50% Improvement From Baseline) Based on All Observed Values Regardless of Rescue Treatment at Week 16

    The EASI score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Percentage of participants who achieved EASI-50 (≥50% Improvement from baseline) at Week 16 were based on all observed values regardless of rescue treatment were reported.

    Time frame: Week 16

  4. Percentage of Participants Who Achieved Eczema Area and Severity Index-75 (EASI-75) (≥75% Improvement From Baseline) Based on Observed Values Set to Missing After Rescue Treatment at Week 16

    The EASI score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Percentage of participants who achieved EASI-75 (≥75% Improvement from baseline) at Week 16 based on observed values set to missing after rescue treatment were reported. Values after first rescue treatment were set to missing and participants with missing EASI score at Week 16 were counted as non-responders. Percentage of participants who achieved EASI-75 (\>= 75% Improvement from baseline) at Week 16 based on observed values set to missing after rescue treatment were reported. Values after first rescue treatment were set to missing and participants with missing EASI score at Week 16 were counted as non-responders.

    Time frame: Week 16

  5. Percentage of Participants Who Achieved Eczema Area and Severity Index-75 (EASI-75) (≥75% Improvement From Baseline) Based on All Observed Values Regardless of Rescue Treatment at Week 16

    The EASI score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Percentage of participants who achieved EASI-75 (≥75% Improvement from baseline) at Week 16 based on all observed values regardless of rescue treatment were reported.

    Time frame: Week 16

  6. Percentage of Participants Who Achieved Eczema Area and Severity Index-90 (EASI-90) (≥90% Improvement From Baseline) Based on Observed Values Set to Missing After Rescue Treatment at Week 16

    The EASI score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Percentage of participants who achieved EASI-90 (≥90% Improvement from baseline) at Week 16 based on observed values set to missing after rescue treatment were reported. Values after first rescue treatment were set to missing and participants with missing EASI score at Week 16 were counted as non-responders.

    Time frame: Week 16

  7. Percentage of Participants Who Achieved Eczema Area and Severity Index-90 (EASI-90) (≥90% Improvement From Baseline) Based on All Observed Values Regardless of Rescue Treatment at Week 16

    The EASI score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Percentage of participants who achieved EASI-90 (≥90% Improvement from baseline) at Week 16 based on all observed values regardless of rescue treatment were reported.

    Time frame: Week 16

  8. Absolute Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16

    The EASI score was used to measure the severity and extent of AD and measures erythema, induration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Absolute change from baseline in EASI score at Week 16 was reported.

    Time frame: Week 16

  9. Absolute Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on All Observed Values Regardless of Rescue Treatment at Week 16

    The EASI score was used to measure the severity and extent of AD and measures erythema, induration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Absolute change from baseline in EASI score at Week 16 based on all observed values regardless of rescue treatment was reported.

    Time frame: Week 16

  10. Percentage of Participants With Both Investigator Global Assessment (IGA) Score 0 or 1 (on the 0 to 5 IGA Scale) and a Reduction From Baseline of ≥2 Points Based on Observed Values Set to Missing After Rescue Treatment at Week 16

    IGA was an assessment scale used to determine severity of AD and clinical response to treatment on a 5 point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response was an IGA score of 0 (clear) or 1 (almost clear). Participants with both IGA score of "0" or "1" and a reduction from baseline of \>= 2 points at Week 16 based on observed values set to missing after rescue treatment were reported. Values after first rescue treatment were set to missing and participants with missing IGA score at Week 16 were counted as non-responders.

    Time frame: Week 16

  11. Percentage of Participants With Both IGA Score 0 or 1 (on the 0 to 5 IGA Scale) and a Reduction From Baseline of ≥2 Points Based on All Observed Values Regardless of Rescue Treatment at Week 16

    IGA was an assessment scale used to determine severity of AD and clinical response to treatment on a 5 point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response was an IGA score of 0 (clear) or 1 (almost clear). Participants with both IGA score of "0" or "1" and a reduction from baseline of ≥2 points at Week 16 based on all observed values regardless of rescue treatment were reported.

    Time frame: Week 16

  12. Absolute Change From Baseline in Weekly Average of Daily Peak Pruritus Numerical Rating Scale (NRS) Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16

    Pruritus NRS was an assessment tool used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, using an electronic questionnaire (e-diary). Participants were asked the following question: how would you rate your itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Absolute change from baseline in weekly average of daily Peak Pruritus NRS score at Week 16 based on observed values set to missing after rescue treatment was reported.

    Time frame: Week 16

  13. Absolute Change From Baseline in Weekly Average of Daily Peak Pruritus NRS Score Based on All Observed Values Regardless of Rescue Treatment at Week 16

    Pruritus NRS was an assessment tool used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, using an electronic questionnaire (e-diary). Participants were asked the following question: how would you rate your itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Absolute change from baseline in weekly average of daily Peak Pruritus NRS score at Week 16 based on all observed values regardless of rescue treatment was reported.

    Time frame: Week 16

  14. Percent Change From Baseline in in Weekly Average of Daily Peak Pruritus NRS Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16

    Pruritus NRS was an assessment tool used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, using an electronic questionnaire (e-diary). Participants were asked the following question: how would you rate your itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Percent change from baseline in weekly average of daily peak pruritus NRS score at Week 16 based on observed values set to missing after rescue treatment was reported. Values after first rescue treatment were set to missing and participants with missing NRS score at Week 16 were counted as non-responders.

    Time frame: Week 16

  15. Percent Change From Baseline in in Weekly Average of Daily Peak Pruritus NRS Score Based on All Observed Values Regardless of Rescue Treatment at Week 16

    Pruritus NRS was an assessment tool used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, using an electronic questionnaire (e-diary). Participants were asked the following question: how would you rate your itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Percent change from baseline in weekly average of daily peak pruritus NRS score at Week 16 based on all observed values regardless of rescue treatment was reported.

    Time frame: Week 16

  16. Percentage of Participants With Improvement (Reduction From Baseline) in Weekly Average of Peak Daily Pruritus NRS ≥4 Based on Observed Values Set to Missing After Rescue Treatment at Week 16

    Pruritus NRS was an assessment tool used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, using an electronic questionnaire (e-diary). Participants were asked the following question: how would you rate your itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Percentage of participants with improvement of weekly average of daily peak pruritus NRS from baseline to Week 16 based on observed values set to missing after rescue treatment were reported. Values after first rescue treatment were set to missing and participants with missing NRS at Week 16 were counted as non-responders.

    Time frame: Week 16

  17. Percentage of Participants With Improvement (Reduction From Baseline) in Weekly Average of Peak Daily Pruritus NRS ≥4 Based on All Observed Values Regardless of Rescue Treatment at Week 16

    Pruritus NRS was an assessment tool used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, using an electronic questionnaire (e-diary). Participants were asked the following question: how would you rate your itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Percentage of participants with improvement of weekly average of daily peak pruritus NRS from baseline to Week 16 based on all observed values regardless of rescue treatment were reported.

    Time frame: Week 16

  18. Time to Onset of Effect on Pruritus (≥4-point Reduction of Weekly Average of Daily Peak Pruritus NRS From Baseline)

    Peak Pruritus NRS is an assessment tool used by participants to report intensity of pruritus (itch) during a 24-hour recall period. Participants were asked the following question: For maximum itch intensity: "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable,' how would you rate your itch at the worst moment during the previous 24 hours?" Due to study discontinuation, not all planned participants were enrolled. For those already enrolled, the study drug was discontinued and participants were transitioned to post-treatment follow-up period. A large amount of data remained uncollected as not all enrolled participants completed all planned study visits and procedures for assessments for some endpoints. Therefore, this endpoint was removed and no data was collected for this outcome measure.

    Time frame: Week 16

  19. Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) at Week 16

    The SCORAD index is a clinical tool for assessing the severity of atopic dermatitis (AD). Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease). Due to study discontinuation, not all planned participants were enrolled. For those already enrolled, the study drug was discontinued and participants were transitioned to post-treatment follow-up period. A large amount of data remained uncollected as not all enrolled participants completed all planned study visits and procedures for assessments for some endpoints. Therefore, this endpoint was removed and no data was collected for this outcome measure.

    Time frame: Week 16

  20. Absolute Change From Baseline in Percent Body Surface Area (BSA) of Atopic Dermatitis (AD) Involvement at Week 16

    BSA affected by AD will be assessed for each section of the body using the rule of nines (the possible highest score for each region is: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]) and will be reported as a percentage of all major body sections combined. The proportion assigned to different body regions is different in younger children as compared to older children (head and neck area is assigned a higher proportion in younger children as compared to older children). Due to study discontinuation, not all planned participants were enrolled. For those already enrolled, the study drug was discontinued and participants were transitioned to post-treatment follow-up period. A large amount of data remained uncollected as not all enrolled participants completed all planned study visits and procedures for assessments for some endpoints. Therefore, this endpoint was removed and no data was collected for this outcome measure.

    Time frame: Week 16

  21. Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and Adverse Events of Special Interest (AESIs) From Baseline up to Week 16

    Adverse Event (AE): any untoward medical occurrence in a participant administered a study drug which may/may not have a causal relationship with study drug. Serious AE (SAE): any untoward medical occurrence that resulted in any of following outcomes: death, life-threatening, required initial/prolonged in-participant hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect/considered as medically important event. TEAE: AEs starting/worsening after first intake of study drug. TEAEs included: SAEs and Non-SAEs. AESI included: Anaphylactic reactions; Systemic/severe hypersensitivity reactions; Malignancy; Helminthic infections; Suicide-related events; Severe injection site reactions; Mycosis fungoides/other forms of cutaneous T-cell lymphoma; any clinical endoparasitosis; Conjunctivitis and significant Alanine aminotransferase (ALT) elevation. Number of participants with TEAEs, Serious TEAES and AESIs from baseline up to Week 16 were reported.

    Time frame: Baseline up to Week 16

  22. Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and Adverse Events of Special Interest (AESIs) From Baseline up to Week 36

    AE: any untoward medical occurrence in a participant administered a study drug which may/may not have a causal relationship with study drug. SAE: any untoward medical occurrence that resulted in any of following outcomes: death, life-threatening, required initial/prolonged in-participant hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect/considered as medically important event. TEAE: AEs starting/worsening after first intake of study drug. TEAEs included both SAEs and Non-SAEs. AESI included: Anaphylactic reactions; Systemic/severe hypersensitivity reactions; Malignancy; Helminthic infections; Suicide-related events; Severe injection site reactions; Mycosis fungoides/other forms of cutaneous T-cell lymphoma; any clinical endoparasitosis; Conjunctivitis and significant ALT elevation. Number of participants with TEAEs, Serious TEAES and AESIs from baseline up to Week 36 were reported.

    Time frame: Baseline up to Week 36

  23. Number of Participants With Positive Treatment-Emergent Anti-drug Antibodies (ADA) to REGN3500 and Dupilumab

    Treatment-Emergent (TE) ADA: any positive post baseline assay response when baseline results were negative/missing. TE ADA responses were further classified as: - persistent (treatment-emergent positive ADA response detected in at least 2 consecutive post baseline samples separated by at least a 16-week post baseline period \[based on nominal sampling time\], with no ADA-negative samples in-between, regardless of any missing samples or a positive response at the last ADA sampling time point),- indeterminate (a positive assay response at the last collection time point only, regardless of any missing samples), - transient (not persistent/indeterminate, regardless of any missing samples). Here, "Number of Participants Analysed" signifies those participants who were evaluable for this endpoint.

    Time frame: Baseline up to Week 36

  24. Serum Concentration of Functional REGN3500

    Serum Concentration of Functional REGN3500 was reported. Data was reported for REGN3500 300 mg Q2W and REGN3500 300 mg + Dupilumab 300 mg Q2W arms only

    Time frame: Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, and 36

  25. Serum Concentration of Functional Dupilumab

    Serum Concentration of Functional Dupilumab was reported.

    Time frame: Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, and 36

07

Results

Posted Nov 1, 2021
Limitations and caveats
The decision was made by the sponsor to terminate the study on 12 Feb 2020 due to lack of efficacy. Study enrollment was not complete at that time, therefore planned sample sizes were not met. Participants discontinued study drug and transitioned into the post-treatment follow-up period. As a result of the decision to terminate the study, all statistical analyses were descriptive and no hypothesis testing was performed.

Participant flow

A total of 299 participants were screened at sites in Republic of Korea, United States of America, Germany, Poland, Czech Republic, Belgium and Spain. Out of 299 participants, 206 participants met eligibility criteria and randomized in this study.

Participant flow — Overall Study
MilestonePlacebo Q2WREGN3500 300 mg Q2WDupilumab 300 mg Q2WREGN3500 300 mg + Dupilumab 300 mg Q2W
Started51525152
Treated50525152
Completed20242722
Not completed31282430
Withdrew: Withdrawal by subject26252326
Withdrew: Lost to follow-up3211
Withdrew: Physician decision1001
Withdrew: Adverse event0101
Withdrew: Death0001
Withdrew: Randomized but never treated1000

Outcome measures

PrimaryPercent Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16

The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, induration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Percent change from baseline in EASI score at Week 16 based on observed values set to missing after rescue treatment was reported. Values after first rescue treatment were set to missing and participants with missing EASI score at Week 16 were counted as non-responders.

Time frame:
Week 16
Reported as:
Mean · Percentage of Change
Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16
Percentage of ChangePlacebo Q2WREGN3500 300 mg Q2WDupilumab 300 mg Q2WREGN3500 300 mg + Dupilumab 300 mg Q2W
Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16-52.4 ± 31.86-66.6 ± 22.46-77.8 ± 23.73-76.9 ± 20.79
SecondaryPercent Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on All Observed Values Regardless of Rescue Treatment at Week 16

The EASI score was used to measure the severity and extent of AD and measures erythema, induration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Percent change from baseline in EASI score at Week 16 based on all observed values regardless of rescue treatment was reported.

Time frame:
Week 16
Reported as:
Mean · Percentage of Change
Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on All Observed Values Regardless of Rescue Treatment at Week 16
Percentage of ChangePlacebo Q2WREGN3500 300 mg Q2WDupilumab 300 mg Q2WREGN3500 300 mg + Dupilumab 300 mg Q2W
Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on All Observed Values Regardless of Rescue Treatment at Week 16-46.6 ± 36.58-58.0 ± 29.69-77.4 ± 22.59-75.8 ± 19.66
SecondaryPercentage of Participants Who Achieved Eczema Area and Severity Index-50 (EASI-50) (Greater Than or Equal to [≥] 50 Percent [%] Improvement From Baseline) Based on Observed Values Set to Missing After Rescue Treatment at Week 16

The EASI score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Percentage of participants who achieved EASI-50 (≥50% Improvement from baseline) at Week 16 based on observed values set to missing after rescue treatment were reported. Values after first rescue treatment were set to missing and participants with missing EASI score at Week 16 were counted as non-responders.

Time frame:
Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved Eczema Area and Severity Index-50 (EASI-50) (Greater Than or Equal to [≥] 50 Percent [%] Improvement From Baseline) Based on Observed Values Set to Missing After Rescue Treatment at Week 16
Percentage of ParticipantsPlacebo Q2WREGN3500 300 mg Q2WDupilumab 300 mg Q2WREGN3500 300 mg + Dupilumab 300 mg Q2W
Percentage of Participants Who Achieved Eczema Area and Severity Index-50 (EASI-50) (Greater Than or Equal to [≥] 50 Percent [%] Improvement From Baseline) Based on Observed Values Set to Missing After Rescue Treatment at Week 1657.978.695.585.0
SecondaryPercentage of Participants Who Achieved Eczema Area and Severity Index-50 (EASI-50) (≥50% Improvement From Baseline) Based on All Observed Values Regardless of Rescue Treatment at Week 16

The EASI score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Percentage of participants who achieved EASI-50 (≥50% Improvement from baseline) at Week 16 were based on all observed values regardless of rescue treatment were reported.

Time frame:
Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved Eczema Area and Severity Index-50 (EASI-50) (≥50% Improvement From Baseline) Based on All Observed Values Regardless of Rescue Treatment at Week 16
Percentage of ParticipantsPlacebo Q2WREGN3500 300 mg Q2WDupilumab 300 mg Q2WREGN3500 300 mg + Dupilumab 300 mg Q2W
Percentage of Participants Who Achieved Eczema Area and Severity Index-50 (EASI-50) (≥50% Improvement From Baseline) Based on All Observed Values Regardless of Rescue Treatment at Week 1652.265.296.287.5
SecondaryPercentage of Participants Who Achieved Eczema Area and Severity Index-75 (EASI-75) (≥75% Improvement From Baseline) Based on Observed Values Set to Missing After Rescue Treatment at Week 16

The EASI score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Percentage of participants who achieved EASI-75 (≥75% Improvement from baseline) at Week 16 based on observed values set to missing after rescue treatment were reported. Values after first rescue treatment were set to missing and participants with missing EASI score at Week 16 were counted as non-responders. Percentage of participants who achieved EASI-75 (\>= 75% Improvement from baseline) at Week 16 based on observed values set to missing after rescue treatment were reported. Values after first rescue treatment were set to missing and participants with missing EASI score at Week 16 were counted as non-responders.

Time frame:
Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved Eczema Area and Severity Index-75 (EASI-75) (≥75% Improvement From Baseline) Based on Observed Values Set to Missing After Rescue Treatment at Week 16
Percentage of ParticipantsPlacebo Q2WREGN3500 300 mg Q2WDupilumab 300 mg Q2WREGN3500 300 mg + Dupilumab 300 mg Q2W
Percentage of Participants Who Achieved Eczema Area and Severity Index-75 (EASI-75) (≥75% Improvement From Baseline) Based on Observed Values Set to Missing After Rescue Treatment at Week 1631.635.763.660.0
SecondaryPercentage of Participants Who Achieved Eczema Area and Severity Index-75 (EASI-75) (≥75% Improvement From Baseline) Based on All Observed Values Regardless of Rescue Treatment at Week 16

The EASI score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Percentage of participants who achieved EASI-75 (≥75% Improvement from baseline) at Week 16 based on all observed values regardless of rescue treatment were reported.

Time frame:
Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved Eczema Area and Severity Index-75 (EASI-75) (≥75% Improvement From Baseline) Based on All Observed Values Regardless of Rescue Treatment at Week 16
Percentage of ParticipantsPlacebo Q2WREGN3500 300 mg Q2WDupilumab 300 mg Q2WREGN3500 300 mg + Dupilumab 300 mg Q2W
Percentage of Participants Who Achieved Eczema Area and Severity Index-75 (EASI-75) (≥75% Improvement From Baseline) Based on All Observed Values Regardless of Rescue Treatment at Week 1626.130.461.558.3
SecondaryPercentage of Participants Who Achieved Eczema Area and Severity Index-90 (EASI-90) (≥90% Improvement From Baseline) Based on Observed Values Set to Missing After Rescue Treatment at Week 16

The EASI score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Percentage of participants who achieved EASI-90 (≥90% Improvement from baseline) at Week 16 based on observed values set to missing after rescue treatment were reported. Values after first rescue treatment were set to missing and participants with missing EASI score at Week 16 were counted as non-responders.

Time frame:
Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved Eczema Area and Severity Index-90 (EASI-90) (≥90% Improvement From Baseline) Based on Observed Values Set to Missing After Rescue Treatment at Week 16
Percentage of ParticipantsPlacebo Q2WREGN3500 300 mg Q2WDupilumab 300 mg Q2WREGN3500 300 mg + Dupilumab 300 mg Q2W
Percentage of Participants Who Achieved Eczema Area and Severity Index-90 (EASI-90) (≥90% Improvement From Baseline) Based on Observed Values Set to Missing After Rescue Treatment at Week 1610.528.640.935.0
SecondaryPercentage of Participants Who Achieved Eczema Area and Severity Index-90 (EASI-90) (≥90% Improvement From Baseline) Based on All Observed Values Regardless of Rescue Treatment at Week 16

The EASI score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Percentage of participants who achieved EASI-90 (≥90% Improvement from baseline) at Week 16 based on all observed values regardless of rescue treatment were reported.

Time frame:
Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved Eczema Area and Severity Index-90 (EASI-90) (≥90% Improvement From Baseline) Based on All Observed Values Regardless of Rescue Treatment at Week 16
Percentage of ParticipantsPlacebo Q2WREGN3500 300 mg Q2WDupilumab 300 mg Q2WREGN3500 300 mg + Dupilumab 300 mg Q2W
Percentage of Participants Who Achieved Eczema Area and Severity Index-90 (EASI-90) (≥90% Improvement From Baseline) Based on All Observed Values Regardless of Rescue Treatment at Week 168.717.438.529.2
SecondaryAbsolute Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16

The EASI score was used to measure the severity and extent of AD and measures erythema, induration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Absolute change from baseline in EASI score at Week 16 was reported.

Time frame:
Week 16
Reported as:
Mean · Scores on a Scale
Absolute Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16
Scores on a ScalePlacebo Q2WREGN3500 300 mg Q2WDupilumab 300 mg Q2WREGN3500 300 mg + Dupilumab 300 mg Q2W
Absolute Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16-13.25 ± 8.073-18.94 ± 9.383-25.40 ± 15.769-23.28 ± 9.177
SecondaryAbsolute Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on All Observed Values Regardless of Rescue Treatment at Week 16

The EASI score was used to measure the severity and extent of AD and measures erythema, induration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Absolute change from baseline in EASI score at Week 16 based on all observed values regardless of rescue treatment was reported.

Time frame:
Week 16
Reported as:
Mean · Scores on a Scale
Absolute Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on All Observed Values Regardless of Rescue Treatment at Week 16
Scores on a ScalePlacebo Q2WREGN3500 300 mg Q2WDupilumab 300 mg Q2WREGN3500 300 mg + Dupilumab 300 mg Q2W
Absolute Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on All Observed Values Regardless of Rescue Treatment at Week 16-12.18 ± 9.819-16.46 ± 10.002-24.06 ± 14.825-21.82 ± 9.008
SecondaryPercentage of Participants With Both Investigator Global Assessment (IGA) Score 0 or 1 (on the 0 to 5 IGA Scale) and a Reduction From Baseline of ≥2 Points Based on Observed Values Set to Missing After Rescue Treatment at Week 16

IGA was an assessment scale used to determine severity of AD and clinical response to treatment on a 5 point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response was an IGA score of 0 (clear) or 1 (almost clear). Participants with both IGA score of "0" or "1" and a reduction from baseline of \>= 2 points at Week 16 based on observed values set to missing after rescue treatment were reported. Values after first rescue treatment were set to missing and participants with missing IGA score at Week 16 were counted as non-responders.

Time frame:
Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants With Both Investigator Global Assessment (IGA) Score 0 or 1 (on the 0 to 5 IGA Scale) and a Reduction From Baseline of ≥2 Points Based on Observed Values Set to Missing After Rescue Treatment at Week 16
Percentage of ParticipantsPlacebo Q2WREGN3500 300 mg Q2WDupilumab 300 mg Q2WREGN3500 300 mg + Dupilumab 300 mg Q2W
Percentage of Participants With Both Investigator Global Assessment (IGA) Score 0 or 1 (on the 0 to 5 IGA Scale) and a Reduction From Baseline of ≥2 Points Based on Observed Values Set to Missing After Rescue Treatment at Week 1621.128.636.435.0
SecondaryPercentage of Participants With Both IGA Score 0 or 1 (on the 0 to 5 IGA Scale) and a Reduction From Baseline of ≥2 Points Based on All Observed Values Regardless of Rescue Treatment at Week 16

IGA was an assessment scale used to determine severity of AD and clinical response to treatment on a 5 point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response was an IGA score of 0 (clear) or 1 (almost clear). Participants with both IGA score of "0" or "1" and a reduction from baseline of ≥2 points at Week 16 based on all observed values regardless of rescue treatment were reported.

Time frame:
Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants With Both IGA Score 0 or 1 (on the 0 to 5 IGA Scale) and a Reduction From Baseline of ≥2 Points Based on All Observed Values Regardless of Rescue Treatment at Week 16
Percentage of ParticipantsPlacebo Q2WREGN3500 300 mg Q2WDupilumab 300 mg Q2WREGN3500 300 mg + Dupilumab 300 mg Q2W
Percentage of Participants With Both IGA Score 0 or 1 (on the 0 to 5 IGA Scale) and a Reduction From Baseline of ≥2 Points Based on All Observed Values Regardless of Rescue Treatment at Week 1617.421.738.529.2
SecondaryAbsolute Change From Baseline in Weekly Average of Daily Peak Pruritus Numerical Rating Scale (NRS) Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16

Pruritus NRS was an assessment tool used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, using an electronic questionnaire (e-diary). Participants were asked the following question: how would you rate your itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Absolute change from baseline in weekly average of daily Peak Pruritus NRS score at Week 16 based on observed values set to missing after rescue treatment was reported.

Time frame:
Week 16
Reported as:
Mean · Scores on a Scale
Absolute Change From Baseline in Weekly Average of Daily Peak Pruritus Numerical Rating Scale (NRS) Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16
Scores on a ScalePlacebo Q2WREGN3500 300 mg Q2WDupilumab 300 mg Q2WREGN3500 300 mg + Dupilumab 300 mg Q2W
Absolute Change From Baseline in Weekly Average of Daily Peak Pruritus Numerical Rating Scale (NRS) Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16-2.08 ± 2.825-2.90 ± 1.781-3.16 ± 2.607-3.92 ± 2.433
SecondaryAbsolute Change From Baseline in Weekly Average of Daily Peak Pruritus NRS Score Based on All Observed Values Regardless of Rescue Treatment at Week 16

Pruritus NRS was an assessment tool used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, using an electronic questionnaire (e-diary). Participants were asked the following question: how would you rate your itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Absolute change from baseline in weekly average of daily Peak Pruritus NRS score at Week 16 based on all observed values regardless of rescue treatment was reported.

Time frame:
Week 16
Reported as:
Mean · Scores on a Scale
Absolute Change From Baseline in Weekly Average of Daily Peak Pruritus NRS Score Based on All Observed Values Regardless of Rescue Treatment at Week 16
Scores on a ScalePlacebo Q2WREGN3500 300 mg Q2WDupilumab 300 mg Q2WREGN3500 300 mg + Dupilumab 300 mg Q2W
Absolute Change From Baseline in Weekly Average of Daily Peak Pruritus NRS Score Based on All Observed Values Regardless of Rescue Treatment at Week 16-2.11 ± 2.651-2.87 ± 1.743-3.19 ± 2.532-3.64 ± 2.326
SecondaryPercent Change From Baseline in in Weekly Average of Daily Peak Pruritus NRS Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16

Pruritus NRS was an assessment tool used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, using an electronic questionnaire (e-diary). Participants were asked the following question: how would you rate your itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Percent change from baseline in weekly average of daily peak pruritus NRS score at Week 16 based on observed values set to missing after rescue treatment was reported. Values after first rescue treatment were set to missing and participants with missing NRS score at Week 16 were counted as non-responders.

Time frame:
Week 16
Reported as:
Mean · Percentage of Change
Percent Change From Baseline in in Weekly Average of Daily Peak Pruritus NRS Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16
Percentage of ChangePlacebo Q2WREGN3500 300 mg Q2WDupilumab 300 mg Q2WREGN3500 300 mg + Dupilumab 300 mg Q2W
Percent Change From Baseline in in Weekly Average of Daily Peak Pruritus NRS Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16-26.6 ± 36.71-38.0 ± 22.94-44.9 ± 35.73-60.2 ± 34.87
SecondaryPercent Change From Baseline in in Weekly Average of Daily Peak Pruritus NRS Score Based on All Observed Values Regardless of Rescue Treatment at Week 16

Pruritus NRS was an assessment tool used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, using an electronic questionnaire (e-diary). Participants were asked the following question: how would you rate your itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Percent change from baseline in weekly average of daily peak pruritus NRS score at Week 16 based on all observed values regardless of rescue treatment was reported.

Time frame:
Week 16
Reported as:
Mean · Percentage of Change
Percent Change From Baseline in in Weekly Average of Daily Peak Pruritus NRS Score Based on All Observed Values Regardless of Rescue Treatment at Week 16
Percentage of ChangePlacebo Q2WREGN3500 300 mg Q2WDupilumab 300 mg Q2WREGN3500 300 mg + Dupilumab 300 mg Q2W
Percent Change From Baseline in in Weekly Average of Daily Peak Pruritus NRS Score Based on All Observed Values Regardless of Rescue Treatment at Week 16-27.6 ± 35.04-37.8 ± 21.88-45.1 ± 34.68-55.7 ± 34.22
SecondaryPercentage of Participants With Improvement (Reduction From Baseline) in Weekly Average of Peak Daily Pruritus NRS ≥4 Based on Observed Values Set to Missing After Rescue Treatment at Week 16

Pruritus NRS was an assessment tool used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, using an electronic questionnaire (e-diary). Participants were asked the following question: how would you rate your itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Percentage of participants with improvement of weekly average of daily peak pruritus NRS from baseline to Week 16 based on observed values set to missing after rescue treatment were reported. Values after first rescue treatment were set to missing and participants with missing NRS at Week 16 were counted as non-responders.

Time frame:
Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants With Improvement (Reduction From Baseline) in Weekly Average of Peak Daily Pruritus NRS ≥4 Based on Observed Values Set to Missing After Rescue Treatment at Week 16
Percentage of ParticipantsPlacebo Q2WREGN3500 300 mg Q2WDupilumab 300 mg Q2WREGN3500 300 mg + Dupilumab 300 mg Q2W
Percentage of Participants With Improvement (Reduction From Baseline) in Weekly Average of Peak Daily Pruritus NRS ≥4 Based on Observed Values Set to Missing After Rescue Treatment at Week 1626.716.735.350.0
SecondaryPercentage of Participants With Improvement (Reduction From Baseline) in Weekly Average of Peak Daily Pruritus NRS ≥4 Based on All Observed Values Regardless of Rescue Treatment at Week 16

Pruritus NRS was an assessment tool used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, using an electronic questionnaire (e-diary). Participants were asked the following question: how would you rate your itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Percentage of participants with improvement of weekly average of daily peak pruritus NRS from baseline to Week 16 based on all observed values regardless of rescue treatment were reported.

Time frame:
Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants With Improvement (Reduction From Baseline) in Weekly Average of Peak Daily Pruritus NRS ≥4 Based on All Observed Values Regardless of Rescue Treatment at Week 16
Percentage of ParticipantsPlacebo Q2WREGN3500 300 mg Q2WDupilumab 300 mg Q2WREGN3500 300 mg + Dupilumab 300 mg Q2W
Percentage of Participants With Improvement (Reduction From Baseline) in Weekly Average of Peak Daily Pruritus NRS ≥4 Based on All Observed Values Regardless of Rescue Treatment at Week 1627.820.033.341.2
SecondaryTime to Onset of Effect on Pruritus (≥4-point Reduction of Weekly Average of Daily Peak Pruritus NRS From Baseline)

Peak Pruritus NRS is an assessment tool used by participants to report intensity of pruritus (itch) during a 24-hour recall period. Participants were asked the following question: For maximum itch intensity: "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable,' how would you rate your itch at the worst moment during the previous 24 hours?" Due to study discontinuation, not all planned participants were enrolled. For those already enrolled, the study drug was discontinued and participants were transitioned to post-treatment follow-up period. A large amount of data remained uncollected as not all enrolled participants completed all planned study visits and procedures for assessments for some endpoints. Therefore, this endpoint was removed and no data was collected for this outcome measure.

Time frame:
Week 16

No measurements were reported for this outcome.

SecondaryPercent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) at Week 16

The SCORAD index is a clinical tool for assessing the severity of atopic dermatitis (AD). Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease). Due to study discontinuation, not all planned participants were enrolled. For those already enrolled, the study drug was discontinued and participants were transitioned to post-treatment follow-up period. A large amount of data remained uncollected as not all enrolled participants completed all planned study visits and procedures for assessments for some endpoints. Therefore, this endpoint was removed and no data was collected for this outcome measure.

Time frame:
Week 16

No measurements were reported for this outcome.

SecondaryAbsolute Change From Baseline in Percent Body Surface Area (BSA) of Atopic Dermatitis (AD) Involvement at Week 16

BSA affected by AD will be assessed for each section of the body using the rule of nines (the possible highest score for each region is: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]) and will be reported as a percentage of all major body sections combined. The proportion assigned to different body regions is different in younger children as compared to older children (head and neck area is assigned a higher proportion in younger children as compared to older children). Due to study discontinuation, not all planned participants were enrolled. For those already enrolled, the study drug was discontinued and participants were transitioned to post-treatment follow-up period. A large amount of data remained uncollected as not all enrolled participants completed all planned study visits and procedures for assessments for some endpoints. Therefore, this endpoint was removed and no data was collected for this outcome measure.

Time frame:
Week 16

No measurements were reported for this outcome.

SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and Adverse Events of Special Interest (AESIs) From Baseline up to Week 16

Adverse Event (AE): any untoward medical occurrence in a participant administered a study drug which may/may not have a causal relationship with study drug. Serious AE (SAE): any untoward medical occurrence that resulted in any of following outcomes: death, life-threatening, required initial/prolonged in-participant hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect/considered as medically important event. TEAE: AEs starting/worsening after first intake of study drug. TEAEs included: SAEs and Non-SAEs. AESI included: Anaphylactic reactions; Systemic/severe hypersensitivity reactions; Malignancy; Helminthic infections; Suicide-related events; Severe injection site reactions; Mycosis fungoides/other forms of cutaneous T-cell lymphoma; any clinical endoparasitosis; Conjunctivitis and significant Alanine aminotransferase (ALT) elevation. Number of participants with TEAEs, Serious TEAES and AESIs from baseline up to Week 16 were reported.

Time frame:
Baseline up to Week 16
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and Adverse Events of Special Interest (AESIs) From Baseline up to Week 16
ParticipantsPlacebo Q2WREGN3500 300 mg Q2WDupilumab 300 mg Q2WREGN3500 300 mg + Dupilumab 300 mg Q2W
Participants with TEAEs25242922
Participants with Serious TEAEs1011
Participants with AESIs2012
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and Adverse Events of Special Interest (AESIs) From Baseline up to Week 36

AE: any untoward medical occurrence in a participant administered a study drug which may/may not have a causal relationship with study drug. SAE: any untoward medical occurrence that resulted in any of following outcomes: death, life-threatening, required initial/prolonged in-participant hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect/considered as medically important event. TEAE: AEs starting/worsening after first intake of study drug. TEAEs included both SAEs and Non-SAEs. AESI included: Anaphylactic reactions; Systemic/severe hypersensitivity reactions; Malignancy; Helminthic infections; Suicide-related events; Severe injection site reactions; Mycosis fungoides/other forms of cutaneous T-cell lymphoma; any clinical endoparasitosis; Conjunctivitis and significant ALT elevation. Number of participants with TEAEs, Serious TEAES and AESIs from baseline up to Week 36 were reported.

Time frame:
Baseline up to Week 36
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and Adverse Events of Special Interest (AESIs) From Baseline up to Week 36
ParticipantsPlacebo Q2WREGN3500 300 mg Q2WDupilumab 300 mg Q2WREGN3500 300 mg + Dupilumab 300 mg Q2W
Participants with TEAEs27263528
Participants with Serious TEAEs1121
Participants with AESIs2012
SecondaryNumber of Participants With Positive Treatment-Emergent Anti-drug Antibodies (ADA) to REGN3500 and Dupilumab

Treatment-Emergent (TE) ADA: any positive post baseline assay response when baseline results were negative/missing. TE ADA responses were further classified as: - persistent (treatment-emergent positive ADA response detected in at least 2 consecutive post baseline samples separated by at least a 16-week post baseline period \[based on nominal sampling time\], with no ADA-negative samples in-between, regardless of any missing samples or a positive response at the last ADA sampling time point),- indeterminate (a positive assay response at the last collection time point only, regardless of any missing samples), - transient (not persistent/indeterminate, regardless of any missing samples). Here, "Number of Participants Analysed" signifies those participants who were evaluable for this endpoint.

Time frame:
Baseline up to Week 36
Reported as:
Count of participants · Participants
Number of Participants With Positive Treatment-Emergent Anti-drug Antibodies (ADA) to REGN3500 and Dupilumab
ParticipantsPlacebo Q2WREGN3500 300 mg Q2WDupilumab 300 mg Q2WREGN3500 300 mg + Dupilumab 300 mg Q2W
Number of Participants With Positive Treatment-Emergent Anti-drug Antibodies (ADA) to REGN3500 and Dupilumab0036
SecondarySerum Concentration of Functional REGN3500

Serum Concentration of Functional REGN3500 was reported. Data was reported for REGN3500 300 mg Q2W and REGN3500 300 mg + Dupilumab 300 mg Q2W arms only

Time frame:
Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, and 36
Reported as:
Mean · Milligrams per Liter (mg/L)
Serum Concentration of Functional REGN3500
Milligrams per Liter (mg/L)REGN3500 300 mg Q2WREGN3500 300 mg + Dupilumab 300 mg Q2W
Week 00 ± 00.00373 ± 0.0269
Week 222.8 ± 9.0625.2 ± 9.58
Week 441.6 ± 14.841.9 ± 16.4
Week 858.8 ± 20.563.0 ± 22.8
Week 1267.4 ± 26.774.5 ± 25.7
Week 1673.9 ± 31.482.4 ± 33.5
Week 2033.3 ± 21.945.1 ± 24.2
Week 2413.1 ± 11.923.3 ± 14.4
Week 287.31 ± 5.4912.3 ± 12.5
Week 324.61 ± 4.485.43 ± 4.12
Week 362.42 ± 2.702.79 ± 2.48
SecondarySerum Concentration of Functional Dupilumab

Serum Concentration of Functional Dupilumab was reported.

Time frame:
Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, and 36
Reported as:
Mean · mg/L
Serum Concentration of Functional Dupilumab
mg/LDupilumab 300 mg Q2WREGN3500 300 mg + Dupilumab 300 mg Q2W
Week 00 ± 00.00219 ± 0.0158
Week 251.4 ± 19.050.6 ± 19.0
Week 451.5 ± 23.657.6 ± 26.1
Week 863.0 ± 32.564.9 ± 26.3
Week 1270.4 ± 37.869.6 ± 29.2
Week 1673.4 ± 39.271.6 ± 30.9
Week 2025.8 ± 26.928.0 ± 24.8
Week 244.36 ± 8.976.50 ± 12.5
Week 281.47 ± 3.862.39 ± 7.93
Week 320.0227 ± 0.08500 ± 0
Week 360 ± 00 ± 0

Adverse events

Collected over All Adverse Events (AEs) were collected from signature of the informed consent form up to the end of study (Week 36) regardless of seriousness or relationship to investigational product (IP).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Q2W0/50 (0%)1/50 (2%)17/50 (34%)
R3500 300 mg Q2W0/52 (0%)1/52 (1.9%)15/52 (28.8%)
Dupilumab 300 mg Q2W0/51 (0%)2/51 (3.9%)25/51 (49%)
R3500 300 mg and Dupilumab 300 mg Q2W1/52 (1.9%)1/52 (1.9%)20/52 (38.5%)
Most frequent serious events
Most frequent serious events
EventPlacebo Q2WR3500 300 mg Q2WDupilumab 300 mg Q2WR3500 300 mg and Dupilumab 300 mg Q2W
HypersensitivityImmune system disorders1/500/520/510/52
Intracranial aneurysmNervous system disorders0/500/521/510/52
Ruptured cerebral aneurysmNervous system disorders0/500/521/510/52
SepsisInfections and infestations0/500/520/511/52
TracheobronchitisInfections and infestations0/501/520/510/52
Goodpasture's syndromeRenal and urinary disorders0/500/520/511/52
Cerebrovascular accidentNervous system disorders0/501/520/510/52
EncephalopathyNervous system disorders0/501/520/510/52
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/501/520/510/52
Most frequent other events
Most frequent other events
EventPlacebo Q2WR3500 300 mg Q2WDupilumab 300 mg Q2WR3500 300 mg and Dupilumab 300 mg Q2W
NasopharyngitisInfections and infestations8/505/5211/516/52
Dermatitis atopicSkin and subcutaneous tissue disorders7/507/528/5110/52
ConjunctivitisInfections and infestations1/500/526/511/52
Oral herpesInfections and infestations0/500/524/511/52
HeadacheNervous system disorders2/501/523/511/52
Rhinitis allergicRespiratory, thoracic and mediastinal disorders2/501/523/511/52
Upper respiratory tract infectionInfections and infestations1/500/522/513/52
Urinary tract infectionInfections and infestations0/503/521/510/52
Conjunctivitis allergicEye disorders0/501/522/513/52

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Placebo Q2WREGN3500 300 mg Q2WDupilumab 300 mg Q2WREGN3500 300 mg + Dupilumab 300 mg Q2WTotal
Mean34.9 ± 14.0433.3 ± 12.1938.4 ± 15.8932.1 ± 12.1034.7 ± 13.74
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Q2WREGN3500 300 mg Q2WDupilumab 300 mg Q2WREGN3500 300 mg + Dupilumab 300 mg Q2WTotal
Female1916232280
Male32362830126
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo Q2WREGN3500 300 mg Q2WDupilumab 300 mg Q2WREGN3500 300 mg + Dupilumab 300 mg Q2WTotal
Hispanic or Latino02114
Not Hispanic or Latino51485050199
Unknown or Not Reported02013
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo Q2WREGN3500 300 mg Q2WDupilumab 300 mg Q2WREGN3500 300 mg + Dupilumab 300 mg Q2WTotal
White26293831124
Black or African American163212
Asian2416101969
Other01001
Eczema Area and Severity Index (EASI) Score
Eczema Area and Severity Index (EASI) Score(Scores on a Scale)Placebo Q2WREGN3500 300 mg Q2WDupilumab 300 mg Q2WREGN3500 300 mg + Dupilumab 300 mg Q2WTotal
Mean28.2 ± 9.5429.9 ± 13.0230.6 ± 13.8629.0 ± 10.7429.4 ± 11.87
08

Study locations

66 sites
  • Regeneron Research Site
    Phoenix, Arizona 85259, United States
  • Regeneron Research Site
    Fountain Valley, California 92708, United States
  • Regeneron Research Site
    Long Beach, California 90808, United States
  • Regeneron Research Site
    Los Angeles, California 90025, United States
  • Regeneron Research Site
    Los Angeles, California 90033, United States
  • Regeneron Research Site
    Sacramento, California 95815, United States
  • Regeneron Research Site
    Davie, Florida 33328, United States
  • Regeneron Research Site
    Sandy Springs, Georgia 30328, United States
  • Regeneron Research Site
    Rockville, Maryland 20850, United States
  • Regeneron Research Site
    Bay City, Michigan 48706, United States
  • Regeneron Research Site
    Saint Joseph, Michigan 49085, United States
  • Regeneron Research Site
    Troy, Michigan 48084, United States
  • Regeneron Research Site
    Bronx, New York 10467, United States
  • Regeneron Research Site
    Forest Hills, New York 11375, United States
  • Regeneron Research Site
    New York, New York 10022, United States
  • Regeneron Research Site
    New York, New York 10029, United States
  • Regeneron Research Site
    High Point, North Carolina 27262, United States
  • Regeneron Research Site
    Norman, Oklahoma 73071, United States
  • Regeneron Research Site
    Portland, Oregon 97239, United States
  • Regeneron Research Site
    Pittsburgh, Pennsylvania 15213, United States
  • Regeneron Research Site
    Arlington, Texas 76014, United States
  • Regeneron Research Site
    Richmond, Virginia 23220, United States
  • Regeneron Research Site
    Anderlecht, 1070, Belgium
  • Regeneron Research Site
    Antwerp, 2650, Belgium
  • Regeneron Research Site
    Brussels, 1090, Belgium
  • Regeneron Research Site
    Brussels, 1200, Belgium
  • Regeneron Research Site
    Liege, 4000, Belgium
  • Regeneron Research Site
    Loverval, 6280, Belgium
  • Regeneron Research Site
    Brno, 602 00, Czechia
  • Regeneron Research Site
    Pardubice, 530 02, Czechia
  • Regeneron Research Site
    Praha 1, 110 00, Czechia
  • Regeneron Research Site
    Praha, 130 00, Czechia
  • Regeneron Research Site
    Bad Bentheim, 48455, Germany
  • Regeneron Research Site
    Berlin, 12459, Germany
  • Regeneron Research Site
    Halle/Saale, 06120, Germany
  • Regeneron Research Site
    Hamburg, 20537, Germany
  • Regeneron Research Site
    Hamburg, 22391, Germany
  • Regeneron Research Site
    Hanau, 63450, Germany
  • Regeneron Research Site
    Leipzig, 04103, Germany
  • Regeneron Research Site
    Lubeck, 23538, Germany
  • Regeneron Research Site
    Mahlow, 15831, Germany
  • Regeneron Research Site
    Munchen, 80337, Germany
  • Regeneron Research Site
    Munster, 48149, Germany
  • Regeneron Research Site
    Quedlinburg, 06484, Germany
  • Regeneron Research Site
    Tuebingen, 72076, Germany
  • Regeneron Research Site
    Witten, 58453, Germany
  • Regeneron Research Site
    Gyeonggi-do, 13496, Korea, Republic of
  • Regeneron Research Site
    Gyeonggi-do, 13620, Korea, Republic of
  • Regeneron Research Site
    Gyeonggi-do, 14584, Korea, Republic of
  • Regeneron Research Site
    Gyeonggi-do, 16499, Korea, Republic of
  • Regeneron Research Site
    Gyeonggi-do, 18450, Korea, Republic of
  • Regeneron Research Site
    Incheon, 21431, Korea, Republic of
  • Regeneron Research Site
    Incheon, 21565, Korea, Republic of
  • Regeneron Research Site
    Incheon, 22332, Korea, Republic of
  • Regeneron Research Site
    Seoul, 03080, Korea, Republic of
  • Regeneron Research Site
    Seoul, 03722, Korea, Republic of
  • Regeneron Research Site
    Seoul, 06591, Korea, Republic of
  • Regeneron Research Site
    Seoul, 07441, Korea, Republic of
  • Regeneron Research Site
    Bydgoszcz, 85-065, Poland
  • Regeneron Research Site
    Bydgoszcz, 85-796, Poland
  • Regeneron Research Site
    Iwonicz Zdroj, 38-440, Poland
  • Regeneron Research Site
    Krakow, 30-033, Poland
  • Regeneron Research Site
    Lodz, 90-436, Poland
  • Regeneron Research Site
    Wroclaw, 51-685, Poland
  • Regeneron Research Site
    Barakaldo, 48903, Spain
  • Regeneron Research Site
    Santiago de Compostela, 15706, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2018 to primary completion in Mar 2020, 16 months.

Results were first posted in Nov 2021, 1 year 7 months after primary completion. A results delay was requested in Mar 2021.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2018
First posted
Nov 9, 2018
StartActual
Nov 12, 2018
Primary completionActual
Mar 13, 2020
CompletionActual
Jul 28, 2020
Results delay requested
Mar 12, 2021
Results first posted
Nov 1, 2021
Last update
Nov 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03736967
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Nov 9, 2018
Start date
Nov 12, 2018
Primary completion
Mar 13, 2020
Completion
Jul 28, 2020
Results posted
Nov 1, 2021
Last update
Nov 1, 2021

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Itepekimab · Dupilumab

Start the discussion